FDA Approves Pancreatic Cancer Device That Extends Survival From Israeli-founded Novocure
The FDA has approved Optune Pax, a wearable device developed by Israeli-founded Novocure, for treating advanced pancreatic cancer. This device uses high-frequency electric fields in combination with chemotherapy to interfere with cancer cell division, extending survival by an average of two months and delaying pain worsening by about six months. Novocure, founded by Prof. Yoram Palti, maintains an R&D center in Haifa, with its headquarters now in Switzerland, and its technology (TTFields) has previously been approved for glioblastoma and mesothelioma.
NovoCure (NVCR) Is Up 8.4% After First-in-Decades Pancreatic Cancer Approval - Has The Bull Case Changed?
NovoCure (NVCR) stock rose 8.4% following FDA approval of Optune Pax for locally advanced pancreatic cancer, marking the first new treatment in decades for this condition. This approval validates NovoCure's Tumor Treating Fields technology and strengthens its broader application beyond niche therapies like GBM. However, investors still need to consider ongoing risks such as slow adoption in other indications, reimbursement challenges, and the company's path to profitability despite positive long-term revenue and earnings forecasts.
NovoCure (NASDAQ:NVCR) Trading Down 6.5% - Here's What Happened
NovoCure (NASDAQ:NVCR) shares dropped 6.5% on Friday, trading at $11.71 with significantly reduced volume. The stock is currently near its 50-day and 200-day moving averages, holding a market cap of $1.23 billion. Analysts have a "Hold" consensus rating with a target price of $26.64, while institutional investors own about 84.6% of the company.
Is NovoCure (NVCR) Pricing Reflect Long Term Potential After Recent 24% Weekly Jump
This article analyzes NovoCure's (NVCR) stock valuation following a recent 24% weekly jump, suggesting it may still be undervalued. Using a Discounted Cash Flow (DCF) analysis, the intrinsic value is estimated at $125.57 per share, significantly higher than the current $12.53. The Price-to-Sales (P/S) ratio also indicates undervaluation compared to industry peers and its proprietary "Fair Ratio".
HC Wainwright & Co. Raises NovoCure (NVCR) Price Target to $47
HC Wainwright & Co. has increased its price target for NovoCure (NVCR) to $47 from $39, a significant 20.51% jump, while maintaining a "Buy" rating. This upward adjustment reflects continued confidence in the company, which develops and commercializes Tumor Treating Fields devices for solid tumor cancers. NovoCure's average target price from seven analysts is $24.07, suggesting a potential upside of 129.03% from its current price.
NovoCure Limited's (NASDAQ:NVCR) 26% Dip In Price Shows Sentiment Is Matching Revenues
NovoCure Limited's share price has fallen 26% in the last month, contributing to a 51% loss over the past year. The company's low price-to-sales (P/S) ratio of 1.8x, compared to an industry average of 2.9x, reflects investor sentiment aligning with its revenue outlook. Analysts forecast 12% annual revenue growth for NovoCure over the next three years, significantly lower than the 124% projected for the broader Medical Equipment industry, justifying the suppressed P/S ratio.
Novocure Wins FDA Nod for Optune Pax Pancreatic Cancer Treatment
Novocure has received FDA approval for its Optune Pax device to treat adults with locally advanced pancreatic cancer, used alongside gemcitabine and nab-paclitaxel. The device delivers Tumor Treating Fields (TTFields) to disrupt cancer cell division, and clinical trials demonstrated significant improvement in overall survival and time to pain progression without increased systemic side effects. This marks the first new treatment for locally advanced pancreatic cancer in decades, offering a novel biophysical approach.
NovoCure stock price target raised to $47 from $39 at H.C. Wainwright
H.C. Wainwright has increased its price target for NovoCure Ltd. (NASDAQ:NVCR) to $47.00 from $39.00, maintaining a Buy rating. This adjustment follows the FDA's earlier-than-expected approval of Optune Pax for locally advanced pancreatic cancer, which has raised the probability of success in this indication from 70% to 100% in H.C. Wainwright's model. The company also reported positive preliminary unaudited revenue for 2025, although it faces administrative challenges regarding billing privileges.
NovoCure Limited's (NASDAQ:NVCR) 26% Dip In Price Shows Sentiment Is Matching Revenues
NovoCure Limited (NASDAQ:NVCR) has experienced a significant 26% share price drop in the last month, contributing to a 51% loss over the past year. This decline has pushed its price-to-sales (P/S) ratio to 1.8x, which is considerably lower than the industry average, suggesting that market sentiment aligns with its revenue performance. Analysts forecast a 12% annual revenue growth for NovoCure over the next three years, which pales in comparison to the 124% growth projected for the broader Medical Equipment industry, thus justifying its low P/S ratio.
NovoCure stock price target raised to $47 from $39 at H.C. Wainwright
H.C. Wainwright raised its price target for NovoCure Ltd. (NASDAQ:NVCR) to $47 from $39, maintaining a Buy rating, following the FDA approval of Optune Pax for pancreatic cancer treatment. This approval was earlier than anticipated, leading H.C. Wainwright to increase the probability of success for pancreatic cancer treatment in their model from 70% to 100%. The company also reported preliminary unaudited revenue of $655.4 million for 2025, an 8% increase from the previous year, despite facing a billing privileges revocation from CMS due to an administrative issue.
Novocure (NVCR) Shares Surge on FDA Approval for Optune Pax
Novocure's stock surged 23% after the FDA approved its Optune Pax device for locally advanced pancreatic cancer, to be used with gemcitabine and nab-paclitaxel. While this approval is a significant breakthrough for pancreatic cancer treatment and the company's proprietary TTFields technology, Novocure faces financial challenges including negative margins, high leverage, and a low Altman Z-Score indicating potential bankruptcy risk. Despite these financial concerns, the stock may be undervalued based on its P/S and P/B ratios, and its RSI suggests it's approaching oversold territory.
Novocure shares soar 30% after FDA nod for pancreatic cancer device
Novocure's shares surged over 30% in extended trading after the U.S. FDA approved its Optune Pax device for locally advanced pancreatic cancer. The device, used with chemotherapy, delivers Tumor Treating Fields to disrupt cancer cell division. This approval was based on positive results from the Phase 3 PANOVA-3 trial, showing significant delay in pain progression and improved one-year survival rates.
NovoCure Ltd treatment gains FDA approval for pancreatic cancer
The U.S. Food and Drug Administration (FDA) has approved NovoCure Ltd's treatment for adult patients with locally advanced pancreatic cancer. The treatment is approved for use in combination with gemcitabine and nab-paclitaxel. This approval marks a significant milestone for NovoCure, expanding its portfolio for challenging cancer types and offering new hope for pancreatic cancer patients.
Novocure Ltd FDA Approval of Optune Pax for Pancreatic Cancer
Novocure Ltd (NVCR) announced FDA approval of Optune Pax for locally advanced pancreatic cancer on February 11, 2026. This marks the first FDA-approved treatment for this cancer type in nearly 30 years, demonstrating significant improvement in overall survival and extending the time to pain progression for patients. The device utilizes Tumor Treating Fields to disrupt cancer cell replication.
FDA clears Novocure (NVCR) Optune Pax for locally advanced pancreatic cancer
The FDA has approved Novocure's Optune Pax for treating locally advanced pancreatic cancer in conjunction with gemcitabine and nab-paclitaxel, marking the first new treatment in nearly 30 years for this condition. The approval is based on the Phase 3 PANOVA-3 trial, which demonstrated a statistically significant improvement in overall survival and extended time to pain progression for patients using Optune Pax. This novel wearable device delivers Tumor Treating Fields, offering a new biophysical approach to cancer treatment.
NovoCure (NVCR) Stock Is Trending Overnight - Here's What You Should Know
NovoCure (NVCR) shares surged after the FDA approved Optune Pax for locally advanced pancreatic cancer, marking the first new treatment in nearly 30 years for the condition. The approval is based on positive Phase 3 trial results showing improved overall survival and time to pain progression. Despite the positive news, the stock has fallen significantly over the past year, and its technical indicators suggest a negative long-term trend.
Assessing NovoCure (NVCR) Valuation After Prolonged Share Price Weakness In Tumor Treating Fields Story
NovoCure (NVCR) has experienced a significant share price decline, leading investors to question its valuation. Despite the weakness, Simply Wall St suggests NVCR is undervalued with a fair value of $24.07 compared to its current price of $10.14, due to potential regulatory approvals and market expansion for its TTFields therapy. The article highlights that NovoCure's growth story could be affected by slow TTFields adoption or patchy reimbursement approvals.
Assessing NovoCure (NVCR) Valuation After Prolonged Share Price Weakness In Tumor Treating Fields Story
NovoCure (NVCR) has experienced significant share price decline, leading investors to re-evaluate its valuation. Despite current trading at US$10.14, below a fair value of $24.07, the company is poised for potential regulatory approvals and market expansion in oncology devices starting in 2026. However, its future growth hinges on overcoming risks like stalled TTFields adoption or inconsistent reimbursement approvals.
C WorldWide Group Holding A S Grows Position in NovoCure Limited $NVCR
C WorldWide Group Holding A S increased its stake in NovoCure Limited (NASDAQ:NVCR) by 56.3% during the third quarter, acquiring 350,000 additional shares to own a total of 971,784 shares valued at approximately $12.6 million. Despite this increased institutional interest, NovoCure shares are currently trading down about 12.7%, with a market capitalization near $1.13 billion. Analyst ratings are mixed, with a consensus "Hold" rating and an average price target of $25.50.
Novocure stock hits 52-week low at $10.66 By Investing.com
Novocure Ltd's stock has reached a new 52-week low of $10.66, marking a significant downturn with a 53.16% decline over the past year. Despite a strong gross profit margin and revenue growth, investor confidence has wavered, leading to three analysts revising earnings downward ahead of the company's upcoming report. The company recently reported unaudited revenue of $655.4 million for 2025 and appointed Frank Leonard as CEO, with analysts reiterating positive ratings.
Novocure stock hits 52-week low at $10.66
Novocure Ltd.'s stock has fallen to a new 52-week low of $10.66, reflecting a 53.16% decline over the past year despite strong gross profit margins and revenue growth. InvestingPro analysis suggests the stock is undervalued, and the company holds more cash than debt, potentially offering flexibility. Recent news also shows revenue growth for 2025 and a new CEO appointment.
Novocure stock hits 52-week low at $10.66 By Investing.com
Novocure Ltd.'s stock has fallen to a new 52-week low of $10.66, reflecting a 53.16% decline over the past year despite the company's strong gross profit margin and revenue growth. Analysts consider the stock undervalued, with some revising earnings estimates downward ahead of the upcoming earnings report, though the company maintains a strong cash position. Recent preliminary revenue figures for 2025 showed an increase, and leadership changes have been met with positive analyst ratings.
NovoCure Faces CMS Billing Privileges Revocation
NovoCure (NVCR) announced on January 30, 2026, that its CMS billing privileges were revoked, retroactive to December 17, 2025, due to an administrative issue rather than a substantive failure. The company has filed a Corrective Action Plan, but the timing for reinstatement is uncertain. This revocation is estimated to impact monthly revenue from CMS Payors by approximately $13 million, although services will continue for both existing and new patients during this process.
Piper Sandler reiterates Overweight rating on NovoCure stock
Piper Sandler has reiterated an Overweight rating on NovoCure Ltd. (NASDAQ:NVCR) with a $27.00 price target, citing “clear messaging shifts” under the new CEO, Frank Leonard. The firm highlights NovoCure's commitment to financial guidance and more responsible spending on non-small cell lung cancer initiatives, which are expected to accelerate its path to profitability in a "catalyst-heavy 2026." This follows recent positive financial results for 2025 and a leadership transition.
Hussman Strategic Advisors Inc. Takes $1.09 Million Position in NovoCure Limited $NVCR
Hussman Strategic Advisors Inc. has acquired a new stake of 84,000 shares in NovoCure Limited (NASDAQ:NVCR) worth approximately $1.09 million. Other institutional investors have also adjusted their holdings in NovoCure, which recently topped revenue and EPS estimates but remains unprofitable. Analysts currently have a "Hold" rating on the stock with an average target price of $25.50.
Emerald Mutual Fund Advisers Trust Has $248,000 Stock Position in NovoCure Limited $NVCR
Emerald Mutual Fund Advisers Trust significantly reduced its stake in NovoCure Limited by 91.3% in Q3, selling over 200,000 shares, but still holds 19,173 shares valued at approximately $248,000. Institutional investors collectively own 84.61% of NovoCure's stock, with varying adjustments to their positions. Despite mixed analyst ratings, with an average "Hold" and target price of $25.50, the company's shares are trading around $13.45, with a market cap of $1.51 billion and a negative P/E ratio.
NovoCure Limited (NASDAQ:NVCR) Short Interest Update
NovoCure Limited (NASDAQ:NVCR) experienced a significant 20% increase in short interest during December, reaching 8,333,839 shares, which accounts for about 7.9% of the stock. This corresponds to a short-interest ratio of 7.8 days, based on average daily trading volume. Analyst coverage remains mixed with a consensus "Hold" rating and an average price target of $25.50, despite recent revenue growth and outperforming EPS estimates in its last quarterly report.
Assessing NovoCure: Insights From 4 Financial Analysts
Four financial analysts have provided their assessments of NovoCure (NASDAQ: NVCR), with sentiment ranging from bullish to indifferent. The average 12-month price target is $30.50, reflecting a slight decrease from the previous average. The article also details NovoCure's financial metrics, including its market capitalization, impressive revenue growth, and strong net margin, while noting challenges in its return on assets compared to industry peers.
A Look At NovoCure (NVCR) Valuation After Record 2025 Revenue And CEO Transition
NovoCure (NVCR) is gaining attention after reporting record 2025 revenues of $655 million, appointing Frank Leonard as CEO, and advancing FDA submissions for its tumor treating fields therapies. Despite a 47.74% decline in its one-year return, analysts suggest the stock is undervalued, with a fair value estimate around $24.93 compared to its current $13.77, largely due to potential market expansion and future earnings growth. However, slower prescription growth and reimbursement uncertainty remain key risks to this valuation.
NovoCure (NASDAQ:NVCR) Receives Neutral Rating from Wedbush
Wedbush reaffirmed a "neutral" rating for NovoCure (NASDAQ:NVCR), setting an $18 price target which suggests a 30.7% upside. NovoCure's analyst consensus is currently a "Hold" with an average price target of $25.50, despite the company recently beating quarterly earnings and revenue estimates. The medical equipment provider remains unprofitable with negative net margin and return on equity, and several institutional investors have recently adjusted their stakes in the company.
Leerink Partners Maintains Novocure(NVCR.US) With Buy Rating, Cuts Target Price to $24
Leerink Partners analyst Jonathan Chang has reiterated a Buy rating for Novocure (NVCR.US), despite lowering the target price from $33 to $24. Chang's analysis, from TipRanks data, indicates a 36.8% success rate and a 3.6% average return over the past year. This report provides an update on analyst sentiment for Novocure.
H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Cuts Target Price to $39
H.C. Wainwright analyst Emily Bodnar has maintained a "Buy" rating for Novocure (NVCR.US) but has adjusted the target price downwards from $42 to $39. The analyst, according to TipRanks data, has a 34.0% success rate and an average return of 12.4% over the past year. This information is intended for informational purposes only and not as investment advice.
NovoCure stock holds steady as H.C. Wainwright reiterates Buy rating By Investing.com
H.C. Wainwright has reiterated its Buy rating and $39.00 price target for NovoCure (NASDAQ:NVCR) after the company reported preliminary Q4 and full-year 2025 financial results. NovoCure's revenue for Q4 2025 was $174.4 million, and full-year 2025 revenue reached $655.4 million, an 8% increase from 2024. Despite not yet being profitable, the company shows significant revenue growth and holds more cash than debt, with analyst targets ranging from $13.50 to $42.00.
NovoCure stock holds steady as H.C. Wainwright reiterates Buy rating
H.C. Wainwright has reiterated its Buy rating and a $39.00 price target for NovoCure Ltd. (NASDAQ:NVCR), following the company's preliminary Q4 and full-year 2025 financial results. NovoCure reported increased revenue for both periods, driven by solid growth, and despite not yet being profitable, it maintains a strong gross profit margin and a healthy cash-to-debt ratio. The company continues to advance clinical trials and anticipates national reimbursement in Spain to boost future growth.
Is NovoCure (NVCR) A Rare Opportunity After A 45.9% One Year Share Price Fall
NovoCure (NVCR) has experienced significant share price volatility, with a 45.9% loss over the last year, but Simply Wall St's analysis suggests it is undervalued. A Discounted Cash Flow (DCF) model indicates the stock is 89.7% undervalued, while a Price vs Sales (P/S) ratio analysis also points to a discount compared to its Fair Ratio. The article encourages investors to further explore NovoCure's valuation and consider various narratives to make informed decisions.
HC Wainwright & Co. Maintains Buy Rating on NVCR, Lowers Price Target
HC Wainwright & Co. has reiterated its Buy rating for NovoCure (NVCR) but lowered its price target from $42.00 to $39.00. This update follows a previous increase in the price target by HC Wainwright & Co. in October 2025, and other analysts have also adjusted their ratings and targets for NVCR recently. NovoCure, an oncology company specializing in Tumor Treating Fields devices, has an average target price of $24.07 from seven analysts, suggesting a significant upside from its current price.
NovoCure stock holds steady as H.C. Wainwright reiterates Buy rating
H.C. Wainwright has reiterated its Buy rating and $39.00 price target on NovoCure Ltd. following the company's announcement of preliminary Q4 and full-year 2025 financial results. The company reported increased revenue for both periods, driven by growth in the U.S. market, and analysts suggest the stock is currently undervalued despite not yet being profitable. NovoCure highlighted upcoming clinical trials and national reimbursement in Spain as future growth drivers.
Novocure reports $655 million in preliminary 2025 revenue By Investing.com
Novocure announced preliminary unaudited revenue of $655.4 million for the full year 2025, an 8% increase from the previous year, with fourth-quarter revenue reaching $174.4 million. The company, which focuses on Tumor Treating Fields therapy, reported 4,620 active patients and ended the year with $448.3 million in cash. With a new CEO, Frank Leonard, Novocure anticipates significant clinical milestones in 2026 and aims for profitability.
Cancer therapy Novocure hits record sales, awaits 2026 trial results
Novocure (NASDAQ: NVCR) reported record preliminary unaudited net revenues of $655.4 million for the full year 2025, an 8% increase from the previous year, and $174.4 million for the fourth quarter. The oncology company, which develops Tumor Treating Fields for aggressive cancers, also provided updates on its operational performance, including patient numbers for Optune Gio and Optune Lua. Key clinical and regulatory milestones are anticipated in 2026, including topline data from Phase 2 and Phase 3 trials and FDA decisions on premarket approval applications for TTFields therapy in various cancer types.
Voya Investment Management LLC Sells 64,539,786 Shares of NovoCure Limited $NVCR
Voya Investment Management LLC significantly reduced its stake in NovoCure Limited (NASDAQ:NVCR) during Q3, selling 64,539,786 shares, which represents a 100% reduction, leaving them with 18,614 shares valued at $240,000. NovoCure surprisingly beat Q3 earnings expectations but remains unprofitable with negative margins. Analysts offer a mixed "Hold" rating with an average target price of $25.93 against the stock's current trading price of around $13.77.
NovoCure Ltd (NVCR) Product Pipeline Analysis Report 2025 - ResearchAndMarkets.com
ResearchAndMarkets.com has added the "NovoCure Ltd (NVCR) - Product Pipeline Analysis, 2025 Update" report. This report provides an in-depth analysis of NovoCure's pipeline products, including details on its proprietary Tumor Treating Fields (TTF) technology used to disrupt cancer cell division. The report covers product overviews, development stages, clinical trials, recent developments, and key company information for NovoCure Ltd, an oncology company specializing in novel delivery systems for various cancers.
NovoCure (Nasdaq:NVCR) - Stock Analysis
This report provides a comprehensive stock analysis of NovoCure (NVCR), an oncology company developing tumor treating fields (TTFields) devices. It covers the company's valuation, future growth prospects, past performance, financial health, and dividend policy, along with analyst ratings and recent news. The analysis shows NovoCure is trading below its estimated fair value but is currently unprofitable.
NovoCure Ltd (NVCR) Product Pipeline Analysis Report 2025 - ResearchAndMarkets.com
ResearchAndMarkets.com has added the "NovoCure Ltd (NVCR) - Product Pipeline Analysis, 2025 Update" report to its offerings, providing detailed insights into NovoCure's pipeline products. NovoCure, an oncology company, specializes in developing novel delivery systems, primarily its proprietary Tumor Treating Fields (TTF) technology, for various cancers. The report covers the company's profile, product pipeline analysis by various parameters, ongoing clinical trials, and recent developments.
NovoCure Ltd (NVCR) Product Pipeline Analysis Report 2025 - ResearchAndMarkets.com
ResearchAndMarkets.com has added the "NovoCure Ltd (NVCR) - Product Pipeline Analysis, 2025 Update" report, offering comprehensive data and intelligence on NovoCure's pipeline products. NovoCure, an oncology company headquartered in Zug, Switzerland, specializes in developing and commercializing novel delivery systems, leveraging its proprietary Tumor Treating Fields (TTF) technology for various cancers. The report details the company's profile, products, development stages, clinical trials, and recent developments.
NovoCure Ltd (NVCR) Product Pipeline Analysis Report 2025 - ResearchAndMarkets.com
ResearchAndMarkets.com has added the "NovoCure Ltd (NVCR) - Product Pipeline Analysis, 2025 Update" report to its offerings. This report provides an in-depth analysis of NovoCure's product pipeline, focusing on its proprietary Tumor Treating Fields (TTF) technology for brain, thoracic, and abdomen cancers. The report details the company's profile, major products, pipeline analysis by various parameters, ongoing clinical trials, and recent developments.
NovoCure (NVCR): Exploring Valuation After a Recent Share Price Rebound
NovoCure (NVCR) has seen a recent rebound in its stock price, up about 9% in the past week, despite a negative year-to-date performance. The company is considered 46.1% undervalued compared to its last close, with a fair value near $24.93, driven by ongoing clinical developments and technology enhancements aimed at expanding its oncology market share. However, investors are cautioned about potential risks such as slower-than-expected adoption and reimbursement uncertainties that could impact growth assumptions.
NovoCure (NVCR): Exploring Valuation After a Recent Share Price Rebound
NovoCure (NVCR) has seen a recent rebound with its stock up 9% over the past week, despite a still negative year-to-date performance. Analysts currently value NVCR at $24.93, suggesting it is undervalued compared to its last close of $13.44, driven by ongoing clinical developments and potential market expansion. Investors are questioning whether the market anticipates recovery or if the stock is genuinely undervalued.
Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference
Novocure (NASDAQ: NVCR) announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, scheduled for January 12-15, 2026, in San Francisco. CEO Frank Leonard will present on January 14, at 9:45 a.m. PST, joined by William Doyle and Christoph Brackmann for investor meetings. A live audio webcast will be available on Novocure's investor relations website.
Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference
Novocure (NASDAQ: NVCR) announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, scheduled for January 12-15, 2026, in San Francisco. Frank Leonard, CEO, will present on January 14 at 9:45 a.m. PST, joined by William Doyle and Christoph Brackmann for investor meetings. The presentation will be webcast live and available for replay on Novocure’s investor relations page.
First Week of February 2026 Options Trading For NovoCure (NVCR)
New options contracts for NovoCure Ltd (NVCR) for February 2026 expiration have started trading this week. The article highlights a put contract at a $12.00 strike price and a call contract at a $15.00 strike price, detailing potential strategies and returns for investors. These strategies include selling a put for an attractive entry price or selling a covered call for income, with analysis on implied volatility and probability of expiring worthless.
